Author name: developer developer

Through its subsidiary of PT Saka Farma Laboratories (Kalbe Consumer Health) and the brand Cerebrofort, PT Kalbe Farma Tbk (Kalbe) shows their support towards optimum nutrition as a recipe for Generation Alpha (Gen Alpha) to be champions. Gen Alpha, which is a generation of children being born in 2010-2025 in a digital era, grows up […]

Through PT Forsta Kalmedic Global, PT Kalbe Farma Tbk (Kalbe) commits to provide high quality medical product and equipment innovations. This is also a support towards the government’s program in regards to national health resiliency to support the independence of local pharmaceutical industry. After launching a local surgical thread last year, Forsta is now successful

Through its subsidiary of Kalbe Consumer Health and the Sakatonik ABC brand, PT Kalbe Farma Tbk (Kalbe) highlights common issues on children’s appetite. Kalbe innovates on multivitamin products to help children with their appetite. Kalbe also develops a web-based application with IDI (Ikatan Dokter Anak Indonesia – Indonesian Pediatric Society) to monitor children’s nutritional needs,

Through their subsidiary of PT Global Onkolab Farma, PT Kalbe Farma Tbk (Kalbe) collaborates withPrimayaHospitalGroup to strengthen centralized services in treating cancer cases in Indonesia. This collaboration is marked by the signing of a memorandum of understanding by the Director of PT Kalbe Farma Tbk, Mulialie and the CEO of PrimayaHospitalGroupLeona A. Karnali. “We are

A data from Indonesia’s 2023 Health Survey shows that the number of vision impairment cases is on the rise and it is concerning. 11.2 percent of people who are older than 1 year of age uses tools to help with their eyesight. Another data from the 2019’s World of Vision shows that there are 65

Through its subsidiary of PT Global Onkolab Farma (GOF), PT Kalbe Farma Tbk (Kalbe) officially inaugurates a radioisotope factory that especially produces Fluorodeoxyglucose (FGD) for the early detection of cancer. This inauguration was attended by the Ministry of Health of the Republic of Indonesia, Budi Gunadi Sadikin, the Head of the Food and Drug Supervisory